Loading…

Survival of dogs with pituitary‐dependent hyperadrenocorticism treated twice daily with low doses of trilostane

Background Twice daily low trilostane doses have proven to be effective to manage canine Cushing's syndrome. However, survival and prognostic factors in dogs treated with this protocol have not been evaluated. The aim of the study was to evaluate survival and prognostic factors, including systo...

Full description

Saved in:
Bibliographic Details
Published in:Veterinary record 2022-08, Vol.191 (3), p.no-no
Main Authors: García San José, Paula, Arenas Bermejo, Carolina, Alonso‐Miguel, Daniel, González Sanz, Sandra, Clares Moral, Irene, Portero Fuentes, Miriam, Pérez‐Alenza, María Dolores
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Twice daily low trilostane doses have proven to be effective to manage canine Cushing's syndrome. However, survival and prognostic factors in dogs treated with this protocol have not been evaluated. The aim of the study was to evaluate survival and prognostic factors, including systolic blood pressure (SBP) at diagnosis, in dogs with pituitary‐dependent hypercortisolism (PDH) treated with low trilostane doses. Methods Medical records of 91 dogs newly diagnosed with PDH initially treated with 0.2–1.1 mg/kg of trilostane twice daily were retrospectively included. Survival times were calculated using the Kaplan–Meier estimator. Univariable and multivariable analysis were performed using the Cox proportional hazard regression analysis. Results Overall, median survival was 998 days (range 26–1832 days, 95% confidence interval = 755–1241 days). In the multivariable analysis, age (hazard ratio [HR] = 1.337, p 
ISSN:0042-4900
2042-7670
DOI:10.1002/vetr.1630